Managing DOAC-Associated Bleeding: Effective Strategies

This CME/CNE/CPE-accredited program is tailored to “on-the-ground” clinicians who make critical treatment decisions for patients with significant bleeds while on a DOAC.

Table of Contents

1. Agenda:
2. Educational Objectives:
3. Intended Audience:
4. Time to Complete:
5. Release Date:
6. Expiration Date:
7. Accredited Provider(s)
8. Commercial Supporter:

Agenda:

1. DOAC-Associated Severe Bleeding: What We’ve Learned and Current Updates – Joshua Goldstein, MD, PhD
2. Reversal Options for DOAC-Associated Bleeding: What Do the Data Show – Deborah Siegal, MD, MSc
3. Clinical Use of Reversal Agents: Common Management Pitfalls – Jerrold Levy, MD
4. The Guidelines in 15 Minutes: Key Learnings on Reversing DOACs – Margaret Fang, MD, MPH
5. Systems-Based Approaches to Appropriate Use of DOAC Reversal, Management of Bleeding, and Reinitiating Anticoagulation – Allison Burnett, PharmD, PhC, CACP

Educational Objectives:

Upon completion of the educational activity, participants should be able to:

1. Describe factors that drive bleeding risk in patients on DOACs.
2. Determine when to use DOAC reversal agents.
3. Assess the balance of bleeding and thrombotic risk in patients taking DOACs.
4. Recognize the importance of restarting DOAC therapy after a bleed.
5. Identify systems-based approaches to standardizing anticoagulation reversal management.

Intended Audience:

The intended audience for this program will consist of Physicians, Nurse Practitioners, Physician Assistants, Nurses, and Pharmacists in the fields of Emergency Medicine, Critical Care, and Neurocritical Care.

Time to Complete:

Approx. 100 minutes

Release Date:

10/31/24

Expiration Date:

10/30/25

Accredited Provider(s)

This activity is jointly provided by Boston University Chobanian & Avedisian School of Medicine’s Center for Continuing Education and Vasculearn Network. 

AMA PRA Category 1 Credits^TM
Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and the Vasculearn Network. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with with the extent of their participation in the activity.

Commercial Supporter:

This activity is supported by an educational grant from AstraZeneca.